As of 2025-12-14, the EV/EBITDA ratio of C4 Therapeutics Inc (CCCC) is -1.54. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CCCC's latest enterprise value is 180.56 mil USD. CCCC's TTM EBITDA according to its financial statements is -117.04 mil USD. Dividing these 2 quantities gives us the above CCCC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.0x - 16.5x | 15.1x |
| Forward P/E multiples | 34.2x - 55.9x | 53.4x |
| Fair Price | (40.70) - (19.30) | (40.76) |
| Upside | -1747.7% - -881.2% | -1750.1% |
| Date | EV/EBITDA |
| 2025-12-05 | -1.71 |
| 2025-12-04 | -1.64 |
| 2025-12-03 | -1.82 |
| 2025-12-02 | -1.51 |
| 2025-12-01 | -1.60 |
| 2025-11-28 | -1.74 |
| 2025-11-26 | -1.72 |
| 2025-11-25 | -1.55 |
| 2025-11-24 | -1.53 |
| 2025-11-21 | -1.52 |
| 2025-11-20 | -1.47 |
| 2025-11-19 | -1.57 |
| 2025-11-18 | -1.55 |
| 2025-11-17 | -1.57 |
| 2025-11-14 | -1.54 |
| 2025-11-13 | -1.53 |
| 2025-11-12 | -1.55 |
| 2025-11-11 | -1.55 |
| 2025-11-10 | -1.44 |
| 2025-11-07 | -1.44 |
| 2025-11-06 | -1.47 |
| 2025-11-05 | -1.46 |
| 2025-11-04 | -1.37 |
| 2025-11-03 | -1.55 |
| 2025-10-31 | -1.66 |
| 2025-10-30 | -1.53 |
| 2025-10-29 | -1.58 |
| 2025-10-28 | -1.63 |
| 2025-10-27 | -1.69 |
| 2025-10-24 | -1.53 |
| 2025-10-23 | -1.47 |
| 2025-10-22 | -1.39 |
| 2025-10-21 | -1.53 |
| 2025-10-20 | -1.60 |
| 2025-10-17 | -1.46 |
| 2025-10-16 | -1.55 |
| 2025-10-15 | -1.34 |
| 2025-10-14 | -1.17 |
| 2025-10-13 | -1.24 |
| 2025-10-10 | -1.36 |
| 2025-10-09 | -1.49 |
| 2025-10-08 | -1.34 |
| 2025-10-07 | -1.37 |
| 2025-10-06 | -1.39 |
| 2025-10-03 | -1.38 |
| 2025-10-02 | -1.33 |
| 2025-10-01 | -1.28 |
| 2025-09-30 | -1.34 |
| 2025-09-29 | -1.34 |
| 2025-09-26 | -1.34 |